Dr Maja Bradic Lindh obtained a Medical Doctor degree at the Medical School, University of Novi Sad, Serbia. She worked for five years as a general practitioner and had five years’ working experience as a clinician at the Medical Oncology Department of the Oncology Institute of Vojvodina. She mostly worked with breast cancer patients.
She has been an active member of the Young Oncologists Committee and active member of the Translational Research Working Group of the European Society for Medical Oncology for four years.
She undertook her PhD studies in cancer research at the Cancer Centre Karolinska, Stockholm, Sweden and defended her thesis in April 2011 with the title: “Mechanisms determining efficacy of tyrosine kinase-targeting anti-cancer drugs”.
Dr Bradic Lindh’s most significant publications are in the area of identification of a SOX2-dependent subset of tumour- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile.